Trials / Unknown

UnknownNCT00008164

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Transplantation Using Umbilical Cord And Placental Blood

Status: Unknown
Phase: Phase 2
Study type: Interventional
Enrollment: 30 (estimated)

Sponsor: Herbert Irving Comprehensive Cancer Center · Academic / Other
Sex: All
Age: 60 Years
Healthy volunteers: Not accepted

Summary

RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.

Detailed description

OBJECTIVES: * Determine the response rate of patients with chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis, hereditary immunodeficiency, or storage disorder treated with allogeneic umbilical cord and placental blood transplantation. * Determine the toxicity of this regimen in these patients. * Determine survival in these patients treated with this regimen. * Determine the incidence of graft-versus-host disease in these patients treated with this regimen. OUTLINE: Patients receive a standard preparative regimen for their disease. Following the preparative regimen patients undergo umbilical cord blood stem cell transplantation on day 0. Patients are followed every 1-2 weeks for 6 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 4-5 years.

Conditions

Interventions

Type	Name	Description
PROCEDURE	umbilical cord blood transplantation

Timeline

Start date: 1997-01-01
First posted: 2003-01-27
Last updated: 2013-12-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00008164. Inclusion in this directory is not an endorsement.